Williams C J
CRC Medical Oncology Unit, Southampton General Hospital, U.K.
Cancer Chemother Pharmacol. 1990;25(4):304-5. doi: 10.1007/BF00684891.
Oral idarubicin (40 mg/m2 in 3-4 divided doses over 24 h every 21 days) was tested in a group of patients with drug-resistant ovarian carcinoma. None of 13 patients responded and the study was discontinued. Toxicity was acceptable, with neutropaenia being dose-limiting. It seems unlikely that idarubicin has significant activity in this disease although phase II studies should ideally be conducted in less heavily pretreated patients.
对一组耐药卵巢癌患者进行了口服伊达比星治疗（每21天一次，24小时内分3 - 4次给药，剂量为40mg/m²）。13名患者均无反应，该研究因此中断。毒性反应可接受，中性粒细胞减少为剂量限制性毒性。尽管理想情况下II期研究应在预处理较轻的患者中进行，但伊达比星在这种疾病中似乎不太可能具有显著活性。
